The impairment of thymopoiesis in HCV-infected patients under IFNα therapy is reminiscent of that observed during the acute phase of HIV-1 infection [23] which suggested that long term production of IFNα, as part of the anti-HIV innate immune response, may play a role in the observed thymic defect. The gene discussed is IFNA2; the disease is HIV-1 infection.